Sera Prognostics, Inc. (SERA)

NASDAQ: SERA · IEX Real-Time Price · USD
8.47
-0.13 (-1.51%)
Feb 23, 2024, 4:30 PM EST - Market closed
-1.51%
Market Cap 265.42M
Revenue (ttm) 330,000
Net Income (ttm) -38.06M
Shares Out 31.34M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 336,830
Open 8.45
Previous Close 8.60
Day's Range 8.25 - 8.80
52-Week Range 1.52 - 9.97
Beta 1.44
Analysts Hold
Price Target 2.75 (-67.53%)
Earnings Date Mar 20, 2024

About SERA

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was in... [Read more]

Sector Healthcare
IPO Date Jul 15, 2021
Employees 87
Stock Exchange NASDAQ
Ticker Symbol SERA
Full Company Profile

Financial Performance

In 2022, SERA's revenue was $268,000, an increase of 226.83% compared to the previous year's $82,000. Losses were -$44.19 million, 26.2% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for SERA stock is "Hold" and the 12-month stock price forecast is $2.75.

Price Target
$2.75
(-67.53% downside)
Analyst Consensus: Hold
Stock Forecasts

News

SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESS

SALT LAKE CITY , Dec. 6, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...

2 months ago - PRNewsWire

SERA PROGNOSTICS TO PRESENT AT 35TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE

SALT LAKE CITY , Nov. 22, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...

3 months ago - PRNewsWire

SERA PROGNOSTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS

SALT LAKE CITY , Nov. 8, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...

3 months ago - PRNewsWire

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2023 Financial Results on November 8, 2023

SALT LAKE CITY , Oct. 25, 2023 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomar...

4 months ago - PRNewsWire

SERA PROGNOSTICS TO PRESENT AT CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE 2023

SALT LAKE CITY , Sept. 21, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomar...

5 months ago - PRNewsWire

SERA PROGNOSTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS

SALT LAKE CITY , Aug. 9, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...

7 months ago - PRNewsWire

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2023 Financial Results on August 9, 2023

SALT LAKE CITY , July 31, 2023 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy bioma...

7 months ago - PRNewsWire

Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue

Aligning Management Team given New Refined Commercial Focus on Institutions Starting with Recent Appointment of Board Member Zhenya Lindgardt as Interim President and CEO Engages Leading Strategy Hous...

9 months ago - PRNewsWire

Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO

SALT LAKE CITY , May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...

10 months ago - PRNewsWire

SERA PROGNOSTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS

SALT LAKE CITY , May 10, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...

10 months ago - PRNewsWire

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2023 Financial Results on May 10, 2023

SALT LAKE CITY , April 27, 2023 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biom...

10 months ago - PRNewsWire

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS

SALT LAKE CITY , March 22, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomar...

1 year ago - PRNewsWire

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2022 Financial Results on March 22, 2023

SALT LAKE CITY , March 9, 2023 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomar...

1 year ago - PRNewsWire

SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES

SALT LAKE CITY , Feb. 23, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...

1 year ago - PRNewsWire

Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL

PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay SALT LAKE CITY , Feb. 15, 2023 /PRNewswire/ --...

1 year ago - PRNewsWire

FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICS

– Sera's PreTRM® test-and-treat strategy helps build on Fors Marsh's commitment to investing in its employees to enable a healthy and viable workforce – SALT LAKE CITY and ARLINGTON, Va. , Nov. 29, 20...

1 year ago - PRNewsWire

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS

- Clinical and economic benefits of the PreTRM® test and treat strategy illustrated amongst diverse racial and ethnic backgrounds - SALT LAKE CITY , Nov. 15, 2022 /PRNewswire/ -- Sera Prognostics Inc....

1 year ago - PRNewsWire

SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS

SALT LAKE CITY , Nov. 9, 2022 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...

1 year ago - PRNewsWire

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2022 Financial Results on November 9

SALT LAKE CITY , Oct. 27, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...

1 year ago - PRNewsWire

SONRAVA HEALTH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH CEREBRAE AND SERA PROGNOSTICS

The value created by applying Sera's PreTRM® test and treat strategy enables savings to be shared in an innovative value-based paradigm SALT LAKE CITY, COPPELL, Texas and SAN MATEO, Calif. , Oct. 4, 2...

1 year ago - PRNewsWire

BANNER HEALTH, SERA PROGNOSTICS TEAM UP TO PROVIDE PreTRM® TEST TO COVERED PREGNANT MEMBERS

First and only broadly clinically validated test to provide accurate and actionable information to help reduce the morbidity, mortality, and costs associated with preterm birth   SALT LAKE CITY and PH...

1 year ago - PRNewsWire

SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS

SALT LAKE CITY , Aug. 10, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...

1 year ago - PRNewsWire

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2022 Financial Results on August 10

SALT LAKE CITY, July 28, 2022 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...

1 year ago - PRNewsWire

SERA PROGNOSTICS TO PRESENT AT 42nd ANNUAL WILLIAM BLAIR GROWTH STOCK CONFERENCE

SALT LAKE CITY , June 6, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...

1 year ago - PRNewsWire

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECISE GESTATIONAL AGE

Results show that the validated proteomics predictor has even greater predictive performance to determine risk of spontaneous preterm birth SALT LAKE CITY , May 19, 2022 /PRNewswire/ -- Sera Prognosti...

1 year ago - PRNewsWire